References
- Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am. J. Respir. Crit. Care Med.161, S221–S247 (2000).
- Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst. Rev. (2), CD001363 (2000).
- Long R, Ellis E (Eds). Canadian Tuberculosis Standards (6 ed.). Public Health Agency of Canada, Ottawa Ontario (2007).
- Aspler A, Long R, Trajman A et al. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax65, 582–587 (2010).
- Horsburgh CR Jr, Goldberg S, Bethel J et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest137, 401–409 (2010).
- Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest130, 1712–1717 (2006).
- Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am. J. Respir. Crit. Care Med.170, 445–449 (2004).
- Saukkonen JJ, Cohn DL, Jasmer RM et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care Med.174, 935–952 (2006).
- Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest128, 116–123 (2005).
- Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA281, 1014–1018 (1999).
- LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am. J. Respir. Crit. Care Med.168, 443–447 (2003).
- Smith BM, Schwartzman K, Bartlett G, Menzies D. Adverse events associated with treatment of latent tuberculosis in the general population. CMAJ183(3), E173–E179 (2011).
- A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am. Rev. Respir. Dis.145, 36–41 (1992).
- Polesky A, Farber HW, Gottlieb DJ et al. Rifampin preventive therapy for tuberculosis in Boston’s homeless. Am. J. Respir. Crit. Care Med.154, 1473–1477 (1996).
- Villarino ME, Ridzon R, Weismuller PC et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am. J. Respir. Crit. Care Med.155, 1735–1738 (1997).
- Menzies D, Long R, Trajman A et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann. Intern. Med.149, 689–697 (2008).
- Page KR, Sifakis F, Montes de Oca R et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch. Intern. Med.166, 1863–1870 (2006).
- Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin. Infect. Dis.49, 1883–1889 (2009).
- Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection – United States, 2003. MMWR Morb. Mortal. Wkly Rep.52, 735–739 (2003).
Website
- NICE Guidelines. CG33 Tuberculosis: Full Guideline www.nice.org.uk/guidance/